Developmental delay in fetal Aminopterin/methotrexate syndrome

Miguel Del Campo, Kenjiro Kosaki, F. C. Bennett, Kenneth L. Jones

Research output: Contribution to journalArticlepeer-review

76 Citations (Scopus)


Maternal exposures to aminopterin and methotrexate have been associated with a pattern of malformation which includes prenatal-onset growth deficiency, severe lack of ossification of the calvarium, hypoplastic supraorbital ridges, small, low-set ears, micrognathia, and limb abnormalities. We report on a patient whose mother received methotrexate during the first trimester of pregnancy and who, in addition to the structural anomalies typical of maternal methotrexate exposure, has significant developmental delay. This is the third patient exposed to folic acid antagonists with mental retardation, providing further evidence that developmental delay is one feature of fetal aminopterin-methotrexate syndrome. Therefore, it is recommended that formal developmental testing be performed in all patients prenatally exposed to methotrexate.

Original languageEnglish
Pages (from-to)10-12
Number of pages3
Issue number1
Publication statusPublished - 1999
Externally publishedYes

ASJC Scopus subject areas

  • Embryology
  • Toxicology
  • Developmental Biology
  • Health, Toxicology and Mutagenesis


Dive into the research topics of 'Developmental delay in fetal Aminopterin/methotrexate syndrome'. Together they form a unique fingerprint.

Cite this